GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis - PubMed (original) (raw)

Meta-Analysis

. 2021 Nov 12:2021:8936865.

doi: 10.1155/2021/8936865. eCollection 2021.

Affiliations

Meta-Analysis

GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

Shahla Rezaei et al. Can J Gastroenterol Hepatol. 2021.

Abstract

Aims: This meta-analysis of randomized placebo-controlled clinical trials assessed the effect of glucose-like peptide-1-receptor agonists (GLP-1RA) on the lipid profile and liver enzymes in patients with nonalcoholic fatty liver disease (NAFLD).

Materials and methods: Randomized placebo-controlled trials investigating GLP-1RA on the lipid profile and liver enzymes in patients with NAFLD were searched in PubMed-Medline, Scopus, Web of Science, and Google Scholar databases (from inception to January 2020). A random-effects model and a generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted. Weighted random-effects meta-regression was performed on potential confounders on lipid profile and liver enzyme concentrations.

Results: 12 studies were identified (12 GLP-1RA arms; 677 subjects) that showed treatment with GLP-1RA reduced alanine transaminase (ALT) concentrations (WMD = -10.14, 95%CI = [-15.84, -0.44], P < 0.001), gamma-glutamyl transferase (GGT) (WMD = -11.53, 95%CI = [-15.21,-7.85], P < 0.001), and alaline phosphatase (ALP) (WMD = -8.29, 95%CI = [-11.34, -5.24], P < 0.001). Aspartate aminotransferase (AST) (WMD = -2.95, 95% CI = [-7.26, 1.37], _P_=0.18) was unchanged. GLP-1 therapy did not alter triglycerides (TC) (WMD = -7.07, 95%CI = [-17.51, 3.37], _P_=0.18), total cholesterol (TC) (WMD = -1.17 (-5.25, 2.91), _P_=0.57), high-density lipoprotein (HDL-C) (WMD = 0.97, 95%CI = [-1.63, 3.58], _P_=0.46), or low-density lipoprotein (LDL-C) (WMD = -1.67, 95%CI = [-10.08, 6.74], _P_=0.69) in comparison with controls.

Conclusion: The results of this meta-analysis suggest that GLP-1RA treatment significantly reduces liver enzymes in patients with NAFLD, but the lipid profile is unaffected.

Copyright © 2021 Shahla Rezaei et al.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1

Figure 1

Flowchart of study selection method.

Figure 2

Figure 2

Details of quality assessment of the included papers.

Figure 3

Figure 3

Meta-analysis of weighted mean differences estimates for lipid profiles including (a) total cholesterol, (b) triglycerides, (c) HDL-cholesterol, and (d) LDL-cholesterol in intervention and placebo groups (CI = 95%).

Figure 4

Figure 4

Meta-analysis of weighted mean differences estimates for liver enzymes including (a) aspartate aminotransferase, (b) alanine aminotransferase, (c) gamma-glutamyltransferase, and (d) alkaline phosphatase in intervention and placebo groups (CI = 95%).

References

    1. Araújo A. R., Rosso N., Bedogni G., Tiribelli C., Bellentani S. Global epidemiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: what we need in the future. Liver International . 2018;38:47–51. - PubMed
    1. Hagström H., Nasr P., Ekstedt M., et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long‐term follow‐up study. Hepatology communications . 2018;2(1):48–57. - PMC - PubMed
    1. Wise J. Pioglitazone seems safe and effective for patients with fatty liver disease and diabetes. BMJ . 2016;353:p. i3435. doi: 10.1136/bmj.i3435. - DOI - PubMed
    1. Wong V. W.-S., Chan W.-K., Chitturi S., et al. Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment. Journal of Gastroenterology and Hepatology . 2018;33(1):70–85. doi: 10.1111/jgh.13857. - DOI - PubMed
    1. Schwenger K. J. P. Nonalcoholic Fatty Liver Disease: Investigating the Impact of Bariatric Care and the Role of Immune Function . Toronto, Canada: University of Toronto; 2018.

Publication types

MeSH terms

Substances

LinkOut - more resources